Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC goes after QVC

This article was originally published in The Tan Sheet

Executive Summary

The home shopping channel violated a previous final order prohibiting QVC from using deceptive advertising practices to market weight-loss products, the FTC alleges in a March 24 complaint filed in Eastern Pennsylvania federal court. The commission maintains each airing of programs for Bee-Alive, For Women Only, Lipofactor Cellulite Target Lotion and Lite Bites a violation of the previous order. Programs touted testimonials from patients with cancer, lupus and multiple sclerosis who also claimed to have lost between 30 lbs and 140 lbs. In a same-day 1release, FTC points out the "claims for these products are not only unsubstantiated, but for some, scientifically impossible." Agency seeks monetary civil penalties, consumers redress and to permanently enjoin the Comcast subsidiary from violating the June 2000 order...

You may also be interested in...



A Challenging Q3 For Novartis, But Diovan Generic Delay Offers A Reprieve

The unexpected delay of U.S. generic competition to Diovan helped pad some of the impact felt by Novartis from the loss of exclusivity on the blockbuster hypertension drug. Still, the impact of generics weighed on Novartis’ third quarter sales, and the delay is only a temporary reprieve of the inevitable sales erosion.

Novartis Outsources OTC Production, Cuts SKUs To Speed Product Return

Novartis AG is on target to reopen its OTC manufacturing facility in Lincoln, Neb., in May and begin shipments midyear, but concedes that only a “limited portfolio” will ship from the plant in 2012. It will outsource manufacturing to make up some of the difference and also aggressively will cut SKUs.

Novartis Outsources OTC Production, Cuts SKUs To Speed Product Return

Novartis AG is on target to reopen its OTC manufacturing facility in Lincoln, Neb., in May and begin shipments midyear, but concedes that only a “limited portfolio” will ship from the plant in 2012. It will outsource manufacturing to make up some of the difference and also aggressively will cut SKUs.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel